-
1 . Periodical
A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- 저자
- by Ahn, Inhye E; Zhou, Yinglu; Tyekucheva, Svitlana; Cormier, Hannah; Fernandes, Stacey M, et al.
- 소스
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p1914-1914, 1p
-